N-(cyclopropylmethyl)-5'-(5-ethyl-1,3,4-oxadiazol-2-yl)-2'-methyl-1,1'-biphenyl-4-carboxamide | 515140-03-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(cyclopropylmethyl)-5'-(5-ethyl-1,3,4-oxadiazol-2-yl)-2'-methyl-1,1'-biphenyl-4-carboxamide
• 英文别名: N-(cyclopropylmethyl)-4-[5-(5-ethyl-1,3,4-oxadiazol-2-yl)-2-methylphenyl]benzamide
• CAS: 515140-03-1
• 化学式: C₂₂H₂₃N₃O₂
• 分子量: 361.444
• InChiKey: VEAZXTGDLQXXBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(Cyclopropylmethyl)-5'-(hydrazinocarbonyl)-2'-methyl-1,1'-biphenyl-4-carboxamide 、 原丙酸三乙酯 在 原丙酸三乙酯 、 cyclohexane, ethyl acetate 作用下， 反应 18.0h， 以to yield N-(cyclopropylmethyl)-5′-(5-ethyl-1,3,4-oxadiazol-2-yl)-2′-methyl-1,1′-biphenyl-4-carboxamide (16.9 mg, 78%)的产率得到N-(cyclopropylmethyl)-5'-(5-ethyl-1,3,4-oxadiazol-2-yl)-2'-methyl-1,1'-biphenyl-4-carboxamide
  参考文献：
  名称：

  2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors

  摘要：

  化合物的公式（I）或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。

  公开号：

  US20070112046A1

文献信息

• 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
  申请人：Angell Martyn Richard

  公开号：US20050090491A1

  公开（公告）日：2005-04-28

  Compounds of formula (I) wherein when m is 0 to 4 R1 is selected from C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1-6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1-6alkyl and —(CH2)n—C3-7cycloalkyl; R3 is the group R6 is selected from hydrogen and C1-4alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1-6alkyl; n is selected from 0, 1, 2 and 3; r is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

  化学式为（I）的化合物，其中当m为0至4时，R1从C1-6烷基，C3-7环烷基，C2-6烯基，-SO2NR4R5，-CONR4R5和-COOR4中选择；当m为2至4时，R1还从C1-6烷氧基，羟基，NR4R5，-NR4SO2R5，-NR4SOR5，-NR4COR5和-NR4CONR4R5中选择；R2从氢，C1-6烷基和-(CH2)n-C3-7环烷基中选择；R3为R6基团，R6基团从氢和C1-4烷基中选择；U从甲基和卤素中选择；X和Y各自独立地从氢，甲基和卤素中选择；m从0、1、2、3和4中选择，其中所得碳链的每个碳原子可以选择性地用一个或两个独立选择的C1-6烷基取代；n从0、1、2和3中选择；r从0、1和2中选择；或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
  申请人：Glaxo Group Limited

  公开号：US07166623B2

  公开（公告）日：2007-01-23

  Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

  式(I)的化合物，或其药学上可接受的盐或溶剂合物，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR
  作者：Richard M. Angell、Tony D. Angell、Paul Bamborough、David Brown、Murray Brown、Jacky B. Buckton、Stuart G. Cockerill、Chris D. Edwards、Katherine L. Jones、Tim Longstaff、Penny A. Smee、Kathryn J. Smith、Don O. Somers、Ann L. Walker、Malcolm Willson

  DOI：10.1016/j.bmcl.2007.10.043

  日期：2008.1

  The biphenyl amides are a novel series of p38 MAP kinase inhibitors. Structure-activity relationships of the series against p38 alpha are discussed with reference to the X-ray crystal structure of an example. The series was optimised rapidly to a compound showing oral activity in an in vivo disease model. (C) 2007 Elsevier Ltd. All rights reserved.
• US7166623B2
  申请人：——

  公开号：US7166623B2

  公开（公告）日：2007-01-23